Tempest Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
16.0M
on 2026-06-30, from 1.71M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-13 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
S-3 of 2024-07-19. Not read yet. S-3 ↗
$14.5M
Jefferies, agreement of 2025-02-06. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
0.2 quarters
$779K on 2026-06-30 ÷ $5.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-03-20 | Private placement incl. 0.46M pre-funded | 925,927 | not read | $2.0M | 8-K ↗ |
| 2025-11-24 | Public offering with warrants at $3.50 | not read | $3.625 | $4.2M | 424B5 ↗ |
| 2025-11-24 | Registered direct offering | 487,000 | not read | not read | 8-K ↗ |
| 2025-06-11 | Public offering | not read | $6.25 | $4.6M | 424B5 ↗ |
| 2025-06-11 | Registered direct offering | 405,000 | not read | not read | 8-K ↗ |
Also on file: a 1-for-13 reverse split, 2025-04-04 8-K ↗